Premium
Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety
Author(s) -
Wilde Sofieke,
Jong Maria G.H.,
Le Brun Paul P.H.,
Guchelaar HenkJan,
Schimmel Kirsten J.M.
Publication year - 2018
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.4335
Subject(s) - documentation , medicine , marketing authorization , quality assurance , pharmacovigilance , quality (philosophy) , product (mathematics) , pharmacy , pharmaceutical care , health care , authorization , risk analysis (engineering) , medical emergency , pharmacology , drug , family medicine , computer science , bioinformatics , philosophy , external quality assessment , geometry , mathematics , epistemology , pathology , economics , biology , programming language , economic growth , computer security
Most medicinal products dispensed to patients have marketing authorization (MA) to ensure high quality of the product, safety, and efficacy. However, in daily practice, to treat patients adequately, there is a medical need for drugs that do not hold MA. To meet this medical need, medicinal products are used in clinical care without MA (unlicensed), such as products prepared by (local) pharmacies: the pharmaceutical preparations. Three types of pharmaceutical preparations are distinguished: (i) reconstitution in excess of summary of product characteristics; (ii) adaptation of a licensed medicinal product (outside its official labeling); (iii) medicinal products from an active pharmaceutical ingredient. Although unlicensed, patients may expect the same quality for these unlicensed pharmaceutical preparations as for the licensed medicinal products. To assure this quality, a proper risk‐benefit assessment and proper documentation in (centralized) patient registries and linking to a national pharmacovigilance database should be in place. Based on a risk assessment matrix, requirements for quality assurance can be determined, which has impact on the level of documentation of a pharmaceutical preparation. In this paper, the approach for good documentation including quality assurance and benefit‐risk assessment will be discussed and possibilities for patient registries are described to make these crucial preparations available for regular patient care. KEY POINTS Ensuring pharmaceutical quality and performing a proper benefit‐risk assessment will guarantee safe use of pharmaceutical preparations. Good documentation of (ultra‐)orphan treatments can be collected in centralized patient registries and should be combined with existing information in (inter)national databases and self‐reflection of patients. Linking patient registries to a centralized database for adverse drug events is highly recommended as it increases safety control of the (ultra) orphan pharmaceutical preparations.